PRISMATIC SENSORS AB

Their core work

Prismatic Sensors AB is a Stockholm-based deep-tech SME that develops photon counting detector technology for computed tomography (CT) medical imaging. Their core product is a silicon-based photon counting detector that can resolve individual X-ray photons by energy level, enabling spectral CT scans with higher image quality, lower radiation dose, and the ability to distinguish tissue types that conventional CT cannot separate. They progressed from a feasibility study validating neurological imaging applications to a full Phase 2 development program building a complete photon counting spectral CT system. This positions them as a hardware innovator at the intersection of medical physics, semiconductor detector design, and clinical imaging.

What they specialise in

How they've shifted over time

Prismatic Sensors shows a classic SME Phase 1 → Phase 2 progression rather than a thematic pivot. In 2015, NEUROSPECT was a small feasibility study (EUR 50,000) focused on validating whether photon counting spectral CT had credible neurological imaging applications — a market entry and proof-of-concept exercise. By 2018, having validated the concept, they secured EUR 2.4M under PCSCT to build the full photon counting spectral CT system as a commercial product. The focus did not change direction — it deepened and scaled, moving from application validation to full system engineering and productization.

Prismatic Sensors is on a product-to-market trajectory: they have completed EU-funded development of a photon counting spectral CT system, and a future collaborator should expect a company focused on commercialization, clinical trials, or OEM partnerships with larger imaging device manufacturers.

How they like to work

Prismatic Sensors has acted exclusively as project coordinator across both H2020 grants, which is consistent with the SME Instrument funding scheme — a solo-applicant track designed for single companies commercializing their own technology. No consortium partners are recorded, meaning they operate as an independent development entity rather than a collaborative research hub. For any future collaboration, expect them to come as a technology owner seeking clinical validation partners, distribution networks, or integration agreements with larger medical device companies — not as a participant in someone else's consortium.

Based on available H2020 data, Prismatic Sensors has no recorded consortium partners and no multi-country collaboration footprint — both projects were executed as solo SME Instrument grants. Their network, if any, operates outside the formal H2020 consortium structure.

What sets them apart

Prismatic Sensors occupies a rare niche: a small Swedish company that has built and validated photon counting detector technology for CT — the same fundamental technology that major players like Siemens are now commercializing in premium scanners worth millions. Their value is in the detector physics expertise and the IP developed through PCSCT, not in scale or network breadth. A consortium builder or corporate partner looking for a deep-tech sensor specialist with a working photon counting CT prototype and EU-validated development history would find very few comparable SMEs in Europe.

Highlights from their portfolio

• PCSCT
  At EUR 2.4M, this is one of the larger SME Phase 2 grants in medical imaging and represents the full engineering build-out of a photon counting spectral CT system — a technology now considered the future of clinical CT scanning.
• NEUROSPECT
  A focused EUR 50k Phase 1 feasibility study that validated a specific clinical use case (neurological imaging) for the photon counting technology, demonstrating strategic market entry thinking before the larger investment.